Kidney Cancer Research News
Nivolumab + ipilimumab with immunostimulatory embolization for Stage 4 renal cell carcinoma
February 16, 2023
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
December 28, 2022
Systemic Therapy Development in Von Hippel-Lindau Disease: An Outsized Contribution from an Orphan Disease
October 28, 2022
Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data
October 2022
Treatment of Refractory Metastatic Renal Cell Carcinoma
October 13, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
September 1, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
September 9, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer
August 23, 2022
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
July 1, 2022
Setting a new standard for long-term survival in metastatic kidney cancer
June 1, 2022
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805
June, 2022
Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma
June, 2022
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
June 24, 2022
Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
June 24, 2022
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
June, 2022
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
May 27, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
April 5, 2022
“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer
March 15, 2022
Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
February 1, 2022
Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma
December 1, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease
November 25, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
November 10, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
September 7, 2021
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
August 18, 2021
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
August 13, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
May 27, 2021
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research
May 1, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
April 21, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
March 20, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
February 20, 2021
The Latest Tweets from Consortium Investigators:
; Wonderful #kidneycancer round table w #MikeAtkins, @brian_rini, @PBarataMD to discuss new RCC data 🔥🧡 @ASCO #ASCO23 @OncoAlert
Legendary! Keep that photo for posterity
An absolute honor to round with the @dukemedicine legend himself, Dr. Tony Galanos, during his last week of inpatient oncology. Bonus: Working with 3 of the most brilliant and compassionate residents @IMResidencyDuke has to offer! @austounding Mark Brahier, and Emory Buck!
Congratulations Howard Scher @MSKCancerCenter, our new Giant and a true visionary and luminary in the field of #prostatecancer, who defined key molecular and genetic features of PC. #GiantsCC23 Thanks also to sponsors @OncLive, Pfizer, Exelixis, Stemline, Menarini
#PANTHER trial results coming @ASCO23! For mCRPC, Abi/ Apalutamide combo resulted in strikingly different outcomes for Blacks and Whites. 24 mo OS rate: twice as many Blacks still alive. Saturday 8 AM poster 109, 1:30 discussion #ProstateCancer #ProjectEquity #ASCO2023
An absolute honor to round with the @dukemedicine legend himself, Dr. Tony Galanos, during his last week of inpatient oncology. Bonus: Working with 3 of the most brilliant and compassionate residents @IMResidencyDuke has to offer! @austounding Mark Brahier, and Emory Buck!
Podcast with @shilpaonc available right after the presentation!
Ab#4505 #ASCO23 @ASCO: EV-103 dose escalation/cohort A ≈ 4 yrs f/u➡️after a median of 9 cycles: ORR: 73.3%, DCR: 84.4%, CR: 15.6%, median DOR: 22.1 months, median PFS 12.7 months in 1L cis-ineligible pts with locally advanced/mUC #bladdercancer 👉http://tinyurl.com/mr3enn5z… https://twitter.com/i/web/status/1661852412020396034
ASCO 23 GU cancer highlight @ChrisSweens1 @brian_rini CONTACT-3, THOR, PEACE1, 5 yr KN426 and much more. https://anchor.fm/the-uromigos/episodes/ASCO-23-GU-highlights-e24uif1
Lacrosse (and football) school @NDlacrosse
📸 @FlatTailPhoto
Just in time for summer, the Uromigos Merch store is now open!!
https://the-uromigos.myshopify.com/collections/all
